Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Study probes Epinephrine's role in blood vessel health

NCT ID NCT02692313

Knowledge-focused Sponsor: University of Maryland, Baltimore Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed early-phase study looked at how epinephrine (adrenaline) affects blood vessel function and clotting in 32 healthy adults. Researchers gave participants epinephrine or a placebo and measured changes in artery dilation. The goal was to better understand why people with diabetes face higher heart risks, but the study did not involve diabetes patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Epinephrine (adrenaline)
What this could lead to
If successful, this study could help explain how the body's response to low blood sugar affects blood vessels, potentially pointing toward ways to prevent heart problems in people with diabetes.
What could go wrong
This is a very early study in only 32 healthy people, not those with diabetes. It measures temporary changes in blood vessel function, not long-term health outcomes, so results may not apply to real-world diabetes care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 32 people

The number the study aims to enrol. It can still change while the study runs.

Start date

Jun 2016

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * healthy controls age 18-55 yr. * Body mass index \>21 kg · m-2 Exclusion Criteria: * Pregnant or breastfeeding women * Subjects unwilling or unable to comply with approved contraception measures * Subjects unable to give voluntary informed consent * Subjects on anticoagulant drugs, anemic or with known bleeding diatheses * Subjects with a history of severe, uncontrolled hypertension, heart disease, cerebrovascular incidents * Current tobacco use * Subjects with any known allergies to any of the study medications being used Physical Exam Exclusion Criteria * Uncontrolled severe hypertension (i.e., blood pressure greater than 160/100) * Clinically significant cardiac abnormalities (e.g. heart failure, arrhythmia) * Pneumonia treatment or hospitalization within 2 weeks prior to enrollment (study visit) * Hepatic failure / jaundice * Renal failure * Cerebrovascular accident occurrence or hospitalization within 4 weeks prior to enrollment * Fever greater than 38.0 degrees C Screening Laboratory Tests Exclusion Criteria * Hematocrit lower than 32 % * White blood cell (WBC) count lower than 3 thou/ul or greater than 14 thou/ul * Liver function tests: serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic-pyruvic transaminase (SGPT) greater than twice upper limit of normal range * Alkaline phosphatase greater than 150U/L * Total bilirubin (TBil) greater than 2 mg/dl * Estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m2 * Positive human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C * Any abnormal cardiac response during multi-stage exercise test (if over 40 years of age)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes complications are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Diabetes Complications

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes complications

Contacts and locations

Locations

  • University of Maryland, Baltimore

    Baltimore, Maryland, 21201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.